Alar Pharmaceuticals Inc. (TPEX:6785)

Alar Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,802	1,793	1,406	739.46	455.35	519.07
Short-Term Investments	482.9	502.9	1,025	156.53	30.87	-
Cash & Short-Term Investments	2,285	2,296	2,431	895.99	486.22	519.07
Cash Growth	-2.51%	-5.54%	171.32%	84.28%	-6.33%	-7.47%
Receivables	0.26	-	-	-	0.84	-
Prepaid Expenses	4.35	41.95	2	3.56	9.96	9.62
Other Current Assets	28.68	14.31	8.58	3.47	0.55	0.01
Total Current Assets	2,318	2,353	2,442	903.02	497.57	528.69
Property, Plant & Equipment	13.93	16.95	13.58	12.77	9.78	9.1
Long-Term Investments	69.59	69.17	21.46	-	-	-
Long-Term Deferred Tax Assets	46.97	48.2	48.27	54.97	13	-
Other Long-Term Assets	0.61	0.6	31.2	2.45	2.25	2.11
Total Assets	2,449	2,488	2,556	973.21	522.6	539.91

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	3.02	22.28	6.69	20.48	2.02	2.17
Current Portion of Leases	1.85	3.57	0.3	1.27	1.29	0.68
Current Income Taxes Payable	46.97	46.97	45.67	49.45	-	-
Current Unearned Revenue	-	-	1.25	1.25	-	-
Other Current Liabilities	7.94	1.64	1.16	2.32	2.06	1.61
Total Current Liabilities	59.79	74.47	55.08	74.77	5.37	4.46
Long-Term Leases	-	-	0.31	0.14	1.41	0.27
Long-Term Deferred Tax Liabilities	10.66	8.12	7.39	-	0.33	-
Other Long-Term Liabilities	1.89	1.75	1.49	1.18	0.99	0.81
Total Liabilities	72.34	84.34	64.26	76.09	8.1	5.54

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	668	668	668	570	570	570
Additional Paid-In Capital	1,579	1,579	1,579	-	-	424.04
Retained Earnings	122.43	148.7	245.09	327.12	-55.5	-459.67
Comprehensive Income & Other	7.74	7.74	-	-	-	-
Shareholders' Equity	2,377	2,403	2,492	897.12	514.5	534.37
Total Liabilities & Equity	2,449	2,488	2,556	973.21	522.6	539.91

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.85	3.57	0.6	1.41	2.69	0.95
Net Cash (Debt)	2,283	2,293	2,430	894.58	483.53	518.12
Net Cash Growth	-2.49%	-5.66%	171.69%	85.01%	-6.68%	-7.39%
Net Cash Per Share	34.18	34.32	36.70	15.68	8.48	9.09
Filing Date Shares Outstanding	66.8	66.8	66.8	57	57	57
Total Common Shares Outstanding	66.8	66.8	66.8	57	57	57
Working Capital	2,258	2,278	2,387	828.25	492.2	524.24
Book Value Per Share	35.58	35.98	37.30	15.74	9.03	9.37
Tangible Book Value	2,377	2,403	2,492	897.12	514.5	534.37
Tangible Book Value Per Share	35.58	35.98	37.30	15.74	9.03	9.37
Machinery	-	28.8	27.15	22.99	16.65	16.42
Leasehold Improvements	-	2.2	0.98	0.98	0.98	1.05

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error